Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2009-09-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/1756285609337992 |
| _version_ | 1819005174633463808 |
|---|---|
| author | Monica A. Rojas Noel G. Carlson Thomas L. Miller John W. Rose |
| author_facet | Monica A. Rojas Noel G. Carlson Thomas L. Miller John W. Rose |
| author_sort | Monica A. Rojas |
| collection | DOAJ |
| description | We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant reduction in relapse rate and improvement in Expanded Disability Status Scores (EDSSs) (p < 0.0001). Long-term treatment with daclizumab in RR MS patients has apparent benefit that will require formal confirmation. |
| first_indexed | 2024-12-20T23:48:36Z |
| format | Article |
| id | doaj.art-834c20fb71f941abbe398211c5b6f669 |
| institution | Directory Open Access Journal |
| issn | 1756-2856 |
| language | English |
| last_indexed | 2024-12-20T23:48:36Z |
| publishDate | 2009-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-834c20fb71f941abbe398211c5b6f6692022-12-21T19:22:53ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28562009-09-01210.1177/1756285609337992Long-term daclizumab therapy in relapsing-remitting multiple sclerosisMonica A. RojasNoel G. CarlsonThomas L. MillerJohn W. RoseWe performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant reduction in relapse rate and improvement in Expanded Disability Status Scores (EDSSs) (p < 0.0001). Long-term treatment with daclizumab in RR MS patients has apparent benefit that will require formal confirmation.https://doi.org/10.1177/1756285609337992 |
| spellingShingle | Monica A. Rojas Noel G. Carlson Thomas L. Miller John W. Rose Long-term daclizumab therapy in relapsing-remitting multiple sclerosis Therapeutic Advances in Neurological Disorders |
| title | Long-term daclizumab therapy in relapsing-remitting multiple sclerosis |
| title_full | Long-term daclizumab therapy in relapsing-remitting multiple sclerosis |
| title_fullStr | Long-term daclizumab therapy in relapsing-remitting multiple sclerosis |
| title_full_unstemmed | Long-term daclizumab therapy in relapsing-remitting multiple sclerosis |
| title_short | Long-term daclizumab therapy in relapsing-remitting multiple sclerosis |
| title_sort | long term daclizumab therapy in relapsing remitting multiple sclerosis |
| url | https://doi.org/10.1177/1756285609337992 |
| work_keys_str_mv | AT monicaarojas longtermdaclizumabtherapyinrelapsingremittingmultiplesclerosis AT noelgcarlson longtermdaclizumabtherapyinrelapsingremittingmultiplesclerosis AT thomaslmiller longtermdaclizumabtherapyinrelapsingremittingmultiplesclerosis AT johnwrose longtermdaclizumabtherapyinrelapsingremittingmultiplesclerosis |